"Cellular Immune Response to CancerVax in Patients Receiving Active Immunotherapy for Metastatic Cancers."

According to an abstract submitted by the authors to the Cancer Symposium, jointly sponsored by Society of Surgical Oncology and the World Federation of Surgical Oncology Societies, held March 26-29, 1998, in San Diego, California, "We previously demonstrated that immunization of stage IV melanoma patients with CancerVax elicits both cellular and humoral immune responses and significantly improves survival. CancerVax is a polyvalent vaccine developed from three melanoma cell lines expressing fifteen different well characterized immunogenic antigens. However, nine of these antigens are also found in other types of solid neoplasms. This preliminary study of CancerVax therapy for patients...

Want to see the full article?

• Purchase this article for only $3.00